| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000009371 |
| Receipt No. | R000011017 |
| Official scientific title of the study | Study on evaluation of therapeutic efficacy and search for a therapeutic biomarker in dry eye with rebamipide eye drop treatment. |
| Date of disclosure of the study information | 2012/12/01 |
| Last modified on | 2016/11/23 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Study on evaluation of therapeutic efficacy and search for a therapeutic biomarker in dry eye with rebamipide eye drop treatment. | |
| Title of the study (Brief title) | Evaluation of therapeutic efficacy and therapeutic biomarker in dry eye with rebamipide eye drop treatment. | |
| Region |
|
|
| Condition | ||
| Condition | Dry eye | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Investigation of usefulness of rebamipide eyedrop in dry eye treatment and utility of biomarker in tears to measure the therapeutic effect in dry eye patients. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Comparison of therapeutic effect of dry eye between rebamipide eye drop and hyaluronate sodium eye drop using biomarker in tears. |
| Key secondary outcomes | Investigation of biomarker in tears that is useful for dry eye practice by comparing patients with dry eye and non-dry eye patients. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | YES |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Dry eye (+)
Rebamipide eye drop (+) Sodium hyaluronate eye drop (-) |
|
| Interventions/Control_2 | Dry eye (+)
Rebamipide eye drop (-) Sodium hyaluronate eye drop (+) |
|
| Interventions/Control_3 | Dry eye (-)
Rebamipide eye drop (-) Sodium hyaluronate eye drop (-) |
|
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | a) Patients with dry eye.
1) Male or female of age of 20 years or older. 2) Patients who provided written informed consent for participating in this study. 3) Patients who are diagnosed as dry eye according to the Japan dry eye diagnostic criteria in 2006. 4) Patients with VAS score of 50 or greater in at least one item in symptom. b) Non-dry eye patients. 1) Male or female of age of 20 years or older. 2) Patients, who are visiting the hospital for existing ocular disease other than anterior segment disease, do not have abnormal findings in anterior segment, and are not receiving treatment with eye drops or contact lens. 3) Patients with VAS score of less than 50 in all items for symptom. 4) Patients who understood the purpose of this study and from whom written consent was obtained. |
|||
| Key exclusion criteria | a) Patients with dry eye.
1) Patients with anterior segment disease (including blepharitis, lagophthalmos, blepharospasm, iritis and conjunctivochalasis) other than dry eye (History is excluded). 2) Patients who cannot discontinue eye drops (include all eye drops such as prescribed drug and OTC medicine) except for the study drug or the control drug from the study initiation until the end of study treatment or who expect to use those drugs. 3) Patients with punctal plug or patients whose punctal plug fell off within three months prior to the study drug initiation examination. Patients with a history ofsurgical punctual occlusion are also excluded. 4) Patients with a history of surgery of the ocular surface within 12 months, or patients with a history of intraocular surgery within three months prior to the study drug initiation examination. 5) Patients who have difficulty in sampling. 6) Patients that a study supervisor or a study partaker judged participation in this study to be inappropriate. b) Non-dry eye patients 1) Patients with anterior segment disease. 2) Patients who used eye drops or the contact lens within two weeks prior to study initiation. 3) Patients with a history of surgery of the ocular surface within 12 months or patients with a history of intraocular surgery within three months prior to the study drug initiation examination. 4) Patients who have difficulty in sampling. 5) Patients that a study supervisor or a study partaker judged participation in this study to be inappropriate. |
|||
| Target sample size | 55 | |||
| Research contact person | |
| Name of lead principal investigator | Jun Shoji |
| Organization | Nihon University School of Medicine |
| Division name | Division of Ophthalmology, Department of Visual Sciences |
| Address | Oyaguchikamimachi 30-1, Itabashi-ku, Tokyo, Japan |
| TEL | 03-3972-8111 |
| shojig3589eye@athena.ocn.ne.jp | |
| Public contact | |
| Name of contact person | Jun Shoji |
| Organization | Nihon University School of Medicine |
| Division name | Division of Ophthalmology, Department of Visual Sciences |
| Address | Oyaguchikamimachi 30-1, Itabashi-ku, Tokyo, Japan |
| TEL | 03-3972-8111 |
| Homepage URL | |
| shojig@med.nihon-u.ac.jp | |
| Sponsor | |
| Institute | Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 日本大学医学部付属板橋病院(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000011017 |